Compare Crispr Therapeutics AG (CRSP) vs US Global Jets ETF (JETS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs US Global Jets ETF — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while US Global Jets ETF trades at $30.85. The key difference: US Global Jets ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | JETS | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $33.34 |
52-Week Low | $44.34 | $23.12 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
JETS trades at $31.22, down 2.71% amid Middle East tensions driving fuel costs higher. Technical signals are mixed with a bullish moving average trend but neutral oscillators, while RSI_6 at 20.52 suggests potential oversold conditions. Recent news highlights airline profit pressures from surging fuel expenses, with the global industry slashing 2026 forecasts due to conflict impacts.
Outlook remains cautious as fuel price volatility and geopolitical risks overshadow cyclical recovery potential. Investment opportunity hinges on oil price stabilization and travel demand resilience, but near-term headwinds from elevated costs and competitive gaps pose significant risks to shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
